Co-diagnostics, inc. completes submission to fda for co-dx pcr pro

The company's emergency use authorization submission is for the new co-dx pcr pro instrument and covid-19 test kit, designed for point-of-care and at-home. the menu of tests in development for the platform includes tb, hpv, and a multiplex respiratory panel for flu a/b, covid-19, and rsv salt lake city , dec. 27, 2023 /prnewswire/ -- co-diagnostics, inc. (nasdaq-cm: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted its co-dx™ pcr covid-19 test with co-dx pcr pro™ instrument for review by the u.s. food and drug administration (fda) for emergency use authorization (eua).
CODX Ratings Summary
CODX Quant Ranking